Drugs / NTR-1011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07237659 | Jul 2026 → Mar 2027 expected | rheumatoid arthritis, systemic lupus erythematosus | Neutrolis | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-02 | Neutrolis | Results Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein neutrolis.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-02 | Neutrolis | Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein neutrolis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTR-1011 | “NTR-1011 is a recombinant fusion protein combining human serum albumin (HSA) with DNASE1L3, an enzyme the body normally uses to break down neutrophil extracellular traps (NETs).” NCT07237659 ↗ |
| Modality | Protein / enzyme biologic | “NTR-1011 is a recombinant fusion protein combining human serum albumin (HSA) with DNASE1L3” NCT07237659 ↗ |
| Route | Intravenous | “NTR-1011 will be presented as a solution for intravenous (IV) administration.” NCT07237659 ↗ |